Table 1 Baseline characteristics of patients newly treated with an antifibrotic drug
Characteristic | Patients newly treated with pirfenidone (N = 804) | Patients newly treated with nintedanib (N = 509) | p-value |
|---|---|---|---|
Age at treatment initiation, years | |||
Mean (SD) | 73.2 (8.1) | 72.8 (8.1) | 0.49 |
Median (IQR) | 74.0 (67.0–79.0) | 73.0 (68.0–79.0) | |
Minimum–maximum | 50.0–92.0 | 51.0–97.0 | |
Sex, n (%) | |||
Male | 618 (76.9) | 391 (76.8) | 0.98 |
Female | 186 (23.1) | 118 (23.2) | |
Year of treatment initiation, n (%) | |||
2015 | 513 (63.8) | 86 (16.9) | < 0.01 |
2016 | 291 (36.2) | 423 (83.1) | |
Time from IPF diagnosis to treatment initiation, months | |||
Mean (SD) | 9.0 (15.0) | 10.6 (18.0) | 0.26 |
Median (IQR) | 2.3 (0.0–10.2) | 2.3 (0.0–11.2) | |
Minimum–maximum | 0.0–96.8 | 0.0–100.6 | |
Number of acute respiratory-related hospital admissions during the year prior to treatment initiation, n (%) | |||
0 | 476 (59.2) | 314 (61.7) | 0.58 |
1 | 247 (30.7) | 151 (29.7) | |
2 or more | 81 (10.1) | 44 (8.6) | |
Number of outpatient visits to a hospital physician during the year prior to treatment initiation, n (%) | |||
0 | 83 (10.3) | 48 (9.4) | 0.74 |
1 or 2 | 252 (31.3) | 170 (33.4) | |
3 or 4 | 216 (26.9) | 142 (27.9) | |
5 or more | 253 (31.5) | 149 (29.3) | |
Charlson comorbidity score, n (%) | |||
1–2 | 122 (15.2) | 85 (16.7) | 0.48 |
3–4 | 436 (54.2) | 283 (55.6) | |
5 or more | 246 (30.6) | 141 (27.7) | |
Use of supplemental oxygen at baseline, n (%) | |||
No | 611 (76.0) | 373 (73.3) | 0.27 |
Yes | 193 (24.0) | 136 (26.7) |